Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 17/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.52 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091097 | 0.83 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7092534 | 0.83 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7093844 | 0.82 | OPRM1 (0.53) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7094122 | 0.81 | CYP2D6 (0.52) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7095914 | 0.81 | OPRM1 (0.52) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7092532 | 0.81 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7095389 | 0.81 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7095112 | 0.79 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL6216571 | 0.79 | OPRM1 (0.50) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL7094475 | 0.79 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861425-B2 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | OPRM1 4/4885OPRK1 8/4885OGFRL1 3/4885 |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | OPRM1 2539/4885OPRK1 1273/4885OGFRL1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.